JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors surrounding TriSalus Life Sciences’ promising developments and strategic expansions. The company is actively broadening the use cases for its TriNav systems, particularly in interventional radiology, which has shown clinical benefits in procedures like uterine artery embolization. This approach not only enhances the speed and effectiveness of treatments compared to traditional methods but also opens up new potential applications, such as knee embolization, which could drive further market adoption.
Furthermore, despite a slight miss in revenue expectations for the third quarter of 2025, the company has demonstrated significant year-over-year growth in unique ordering accounts and remains committed to achieving substantial revenue growth for the full year. The launch of new products, including the TriNav FLX, and the expectation of reaching adjusted EBITDA positivity in the first half of 2026, further solidify the company’s growth trajectory and potential, justifying the Buy rating.
In another report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $11.00 price target.